Telavancin for Acute Bacterial Skin and Skin Structure Infections, a Post Hoc Analysis of the Phase 3 ATLAS Trials in Light of the 2013 FDA Guidance.

@article{Pushkin2015TelavancinFA,
  title={Telavancin for Acute Bacterial Skin and Skin Structure Infections, a Post Hoc Analysis of the Phase 3 ATLAS Trials in Light of the 2013 FDA Guidance.},
  author={Richard Pushkin and Steven L. Barriere and Whedy Wang and G. Ralph Corey and Mart{\'i}n E. Stryjewski},
  journal={Antimicrobial agents and chemotherapy},
  year={2015},
  volume={59 10},
  pages={6170-4}
}
Two phase 3 ATLAS trials demonstrated noninferiority of telavancin compared with vancomycin for complicated skin and skin structure infections. Data from these trials were retrospectively evaluated according to 2013 U.S. Food and Drug Administration (FDA) guidance on acute bacterial skin and skin structure infections. This post hoc analysis included… CONTINUE READING